Q-omics provides the consensus-scored EREG profile across patient tissues and cancer cell-line models. EREG expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EREG is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, EREG RNA expression shows 15,996 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where EREG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EREG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EREG survival associations across molecular data types. EREG RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EREG RNA expression–survival associations across cancer types. High EREG expression shows unfavorable associations in KIRC, UVM, CESC, ACC, PAAD and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EREG RNA expression.
This table summarizes EREG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for EREG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EREG shows lower tumor expression in BRCA and LUSC and higher tumor expression in COAD, THCA, LUAD and KIRP. The COAD box plot shows higher EREG RNA expression in tumor versus normal tissue (log2 FC = +1.974, t-test p < 0.001).
This table shows molecular features associated with EREG in patient tissues and cancer cell lines. In patient samples, EREG shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, EREG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_NSCLC_LUAD.
